PE85 - Robot-assisted supine extraperitoneoscopic retroperitoneal lymph node dissection for post chemotherapy residual lymph node mass in testicular cancer: our initial experience

Publication date: September 2019Source: European Urology Supplements, Volume 18, Issue 6Author(s): G.K. Pooleri
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research

Related Links:

CONCLUSIONS: A rigorous use of classifications is mandatory to define staging since initial diagnosis. Applying treatments based on these classifications leads to excellent survival rates (99 % in CSI, 85 % in CSII+). PMID: 31610870 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Condition:   Testicular Cancer Interventions:   Diagnostic Test: Skin biopsy;   Diagnostic Test: Subcutaneous fat biopsy Sponsors:   University Medical Center Groningen;   Dutch Cancer Society Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: 2019Source: European Urology Supplements, Volume 18, Issue 4Author(s): O. Lucas, P. Wilson, W. Ansell, B. Thomas, D. Berney, J. Shamash, C. Alifrangis
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
This study has uncovered a novel role of TDRG1 in reducing chemoresistance during CDDP treatment and provides potential therapeutic strategies for the treatment of human seminoma. PMID: 31496041 [PubMed - as supplied by publisher]
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
ConclusionsThis study represents the largest case series of primary R-RPLND for the treatment of low-stage non-seminomatous germ cell tumors (NSGCT). With 47  months of follow-up and a low rate of adjuvant chemotherapy, intermediate oncologic efficacy appears to be comparable to the gold standard open approach.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
This report describes a 21-year-old man who was refractory to chemotherapy and immunotherapy. Whole exome sequencing and low-depth whole genome sequencing confirmed the KRAS gene amplification, which may lead to the tumor cells' progression and proliferation. After discussion at the molecular tumor board, the patient was offered paclitaxel, carboplatin, and sorafenib (CPS) based on a phase III clinical trial of melanoma with KRAS gene copy gains. After treatment with CPS, the patient achieved excellent curative effects. Because of a nearly 50% frequency of KRAS amplification in chemotherapy-refractory testicular germ cells...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Testicular Cancer | Urology & Nephrology